Dergiler / Journal of Clinical Research in Pediatric Endocrinology / 2017 / Cilt: 9 - Sayı: 2

The Rationale for Growth Hormone Therapy in Children with Short Stature

Sayfa
23–32
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The aim of this review is to provide a critical overview on the daily use of GH in two paradigmatic conditions of non-GH deficient short stature which are children born small for gestational age and with idiopathic short stature, highlighting the available strength of evidence for efficacy and safety

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Growth hormone (GH) was first isolated from cadaver pituitary glands, requiring laborious and expensive collection of glands, followed by extraction and purification of the hormone.
📊
Temel Bulgular & Veri:This limited supply restricted its use to children with severe GH deficiency who were treated with low dosages and suboptimal schedules.
💡
Sonuç & Katkı:The aim of this review is to provide a critical overview on the daily use of GH in two paradigmatic conditions of non-GH deficient short stature which are children born small for gestational age and with idiopathic short stature, highlighting the available strength of evidence for efficacy and safety
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Growth hormone (GH) was first isolated from cadaver pituitary glands, requiring laborious and expensive collection of glands, followed by extraction and purification of the hormone. This limited supply restricted its use to children with severe GH deficiency who were treated with low dosages and suboptimal schedules. The development of recombinant DNA-derived GH, allowed the production of virtually unlimited amounts of GH, leading to the approval for therapy for a large number of childhood conditions characterized by nonGH deficient short stature. The aim of this review is to provide a critical overview on the daily use of GH in two paradigmatic conditions of non-GH deficient short stature which are children born small for gestational age and with idiopathic short stature, highlighting the available strength of evidence for efficacy and safety

🔖

Bu Makaleye Atıf Yap

DEODATİ, A., CİANFARANİ, S. (2017). The Rationale for Growth Hormone Therapy in Children with Short Stature. Journal of Clinical Research in Pediatric Endocrinology, Cilt: 9 - Sayı: 2, 23–32. https://ajindex.com/articles/209884

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Pedicelli S, Peschiaroli E, Violi E, Cianfarani S. Controversies in the definition and treatment of idiopathic short stature (ISS). J Clin Res Pediatr Endocrinol 2009;1:105-115. Epub 2009 Feb 1 2. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008;93:4210- 4217. Epub 2008 Sep 9 3. Stanhope R, Preece MA. Management of constitutional delay of growth and puberty. Arch Dis Child 1988;63:1104-1110. 4. Albanese A, Stanhope R. Predictive factors in the determination of final height in boys with constitutional delay of growth and puberty. J Pediatr 1995;126:545-550. 5. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958;18:901-903. 6. Ranke MB. Clinical experience with authentic recombinant human growth hormone. Acta Paediatr Scand Suppl 1986;325:90-92. 7. Wilton P, Sietnieks A. An open-labelled study of the safety, acute metabolic activity and pharmacokinetic profile of a short-term course of recombinant human growth hormone in healthy volunteers. Clin Endocrinol (Oxf) 1987;26:125-128. 8. Fryklund LM, Bierich JR, Ranke MB. Recombinant human growth hormone. Clin Endocrinol Metab 1986;15:511-535. 9. Takano K, Shizume K, Hibi I, Okuno A, Hanyu K, Suwa S, Nakajima H, Kondo T, Kato K, Iwatani N, Momoi T, Chihara K, Shirakawa E, Kohno H. Treatment of pituitary dwarfism with authentic recombinant human growth hormone (SM-9500). Endocrinol Jpn 1987;34:291-297. 10. Martial JA, Hallewell RA, Baxter JD, Goodman HM. Human growth hormone: complementary DNA cloning and expression in bacteria. Science 1979;205:602-607. 11. Goeddel DV, Heyneker HL, Hozumi T, Arentzen R, Itakura K, Yansura DG, Ross MJ, Miozzari G, Crea R, Seeburg PH. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature 1979;281:544-548. 12. Olson KC, Fenno J, Lin N, Harkins RN, Snider C, Kohr WH, Ross MJ, Fodge D, Prender G, Stebbing N. Purified human growth hormone from E. coli is biologically active. Nature 1981;293:408-411. 13. Hintz RL, Rosenfeld RG, Wilson DM, Bennett A, Finno J, McClellan B, Swift R. Biosynthetic methionyl human growth hormones is biologically active in adult man. Lancet 1982;5:12